Introduction {#section6-2040622316644481}
============

Approximately 80--85% of multiple sclerosis (MS) cases begin with a relapsing--remitting (RR) course \[[@bibr4-2040622316644481]\]. A recent survey indicated that 44% of patients with MS (*n* = 2562) in the United States report having at least one acute exacerbation per year, ranging from less than 1 week to over 6 months in duration \[[@bibr9-2040622316644481]\]. The primary treatment option for relapse is high-dose intravenous or oral corticosteroids \[[@bibr18-2040622316644481]; [@bibr21-2040622316644481]\]; however, not all patients respond adequately to these agents \[[@bibr15-2040622316644481]; [@bibr20-2040622316644481]\]. A review of clinical trials that assessed the use of corticosteroids for MS relapse management concluded that based on both therapeutic response and tolerability profile it is difficult to predict which patients will respond favorably to such treatment \[[@bibr11-2040622316644481]\]. For example, a number of studies investigating the central nervous system have shown that sustained activity at intracellular glucocorticoid receptors can actually result in increased central nervous system inflammation, especially if steroid exposure occurs prior to the injury in question \[[@bibr6-2040622316644481]; [@bibr7-2040622316644481]; [@bibr12-2040622316644481]; [@bibr16-2040622316644481]; [@bibr22-2040622316644481]\]. This response could result in a lack of steroid efficacy in various patients experiencing an MS relapse. Corticosteroids have also been shown to result in various adverse events (AEs) that may negatively impact certain patients with MS, especially those with comorbid disorders, necessitating alternative treatments for acute MS exacerbations \[[@bibr21-2040622316644481]\].

Diabetes, both type 1 and 2 (T1D and T2D), is a prevalent disease in the overall population. A recent retrospective study of administrative data assessed the comorbidity of various diseases in an MS population compared with a matched cohort of the general population over 28 years (1984--2012) \[[@bibr14-2040622316644481]\]. Results indicated that the prevalence of diabetes in the MS population did not differ from that of the matched general population at index start; however, patients with MS and diabetes were found to be at greater risk for mortality than patients with MS without diabetes. These data could suggest that treating patients with MS with concomitant diabetes may require increased monitoring and possible consideration of all treatment options based on individual patient needs.

Treatment for MS relapse can be complex among patients with diabetes for numerous reasons. Corticosteroids have been shown to cause alterations in glucose tolerance and metabolism, and hyperglycemia is a common and rapidly occurring AE following treatment with high-dose steroids during hospitalization \[[@bibr2-2040622316644481]; [@bibr8-2040622316644481]; [@bibr17-2040622316644481]; [@bibr21-2040622316644481]\]. In order to keep blood glucose levels steady during corticosteroid treatment of MS exacerbations in people with diabetes, increasing dosages of insulin may be necessary; however, a recent study found that 40% of patients with MS were insulin resistant \[[@bibr19-2040622316644481]\]. Fluctuations in blood glucose are well known to increase diabetic complications; thus, maintaining steady glucose control throughout MS exacerbation treatment is of great importance.

Adrenocorticotropic hormone (H.P. Acthar Gel, repository corticotropin injection, Mallinckrodt ARD Inc., Hazelwood, MO, USA) is approved to treat MS relapses and is generally used as an alternative to high-dose corticosteroids \[[@bibr13-2040622316644481]; [@bibr21-2040622316644481]\]. Preliminary data from a small crossover study (*n* = 18) presented in 2014 indicate that treatment of healthy controls with Acthar Gel results in fewer drug-related AEs than an intravenous methylprednisolone (IVMP) regimen \[[@bibr1-2040622316644481]\]. In addition, preliminary results (*n* = 4) from a serum cortisol equivalent exposure ratio indicate that patients on Acthar Gel had \<10% of the total steroid exposure of the comparator IVMP \[[@bibr1-2040622316644481]\]. There have been reports of hyperglycemia in some individuals treated with Acthar Gel \[[@bibr2-2040622316644481]; [@bibr3-2040622316644481]; [@bibr10-2040622316644481]\], although no large-scale clinical trials have assessed the prevalence of this AE. Similar to primary treatment with intravenous corticosteroids, the prescribing information for Acthar Gel indicates that it should be used with caution in patients with diabetes and that those treated with the drug should be monitored carefully for signs of hyperglycemia during and after discontinuation of therapy. Clinicians, therefore, should maintain vigilance over blood glucose levels \[[@bibr13-2040622316644481]\].

This case series reflects patient-reported and healthcare provider (HCP)-recorded data from patients with MS and T1D or T2D who either experienced complications or did not adequately respond to previous steroid use for the treatment of an MS relapse. The purpose of this study was to collect information and review patients' experiences with Acthar Gel treatment for MS exacerbations in patients with MS and concomitant diabetes.

Methodology {#section7-2040622316644481}
===========

This is a retrospective description of patients with MS and either T1D or T2D who experienced complications during prior steroid use and had to use alternate treatment. Data were collected from HCP-completed questionnaires regarding their patients with MS and diabetes who were treated with Acthar Gel rather than steroids for MS relapse. The questionnaire was designed to assess the results of Acthar Gel treatment for MS relapse in this specific patient population and included items pertaining to patient demographics, MS history, type of MS, diabetes history, and experience with diabetes treatments (see [Appendix](#app1-2040622316644481){ref-type="app"}). Additional questions addressed prior steroid use, duration of treatment, time to resolution of relapse, and AEs associated with Acthar Gel. HCPs completed the questionnaires based on information that was previously recorded for patients who received treatment with Acthar Gel under their supervision and included both patient-reported and HCP-recorded data. The questionnaire also served as a vehicle to determine if, by chance, these patients kept blood glucose logs, with the understanding that patients with MS usually do not. This study was not designed or powered with the intention of conducting statistical analyses.

Patient confidentiality was maintained throughout the study. An IRB exemption was provided by Western Institutional Review Board, Puyallup, WA, USA, and patients were not required to provide consent.

Results {#section8-2040622316644481}
=======

Approximately 30 HCPs received the questionnaire, and eight completed and returned them to the investigator. Thirteen patients with a mean age of 47.9 years (range 42--69 years) and mean MS disease duration of 11.9 years (range 4--19 years; [Table 1](#table1-2040622316644481){ref-type="table"}) were included. Most patients had RR MS (92.3%), were female (84.6%), and were white (69.2%). Two patients had RR MS and T1D, 10 had RR MS and T2D, and one had progressive-relapsing MS and T2D.

###### 

Demographic data, diabetes history, and prior steroid use.

![](10.1177_2040622316644481-table1)

  Subject                                                        1                                       4                                                                             5                                                                                        7                                                                                                                     8                                                                             9                      10                  11                12                                                                                                     13                          14                                       15                                                                              16
  -------------------------------------------------------------- --------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------- ------------------- ----------------- ------------------------------------------------------------------------------------------------------ --------------------------- ---------------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------
  Age                                                            58                                      52                                                                            50                                                                                       44                                                                                                                    53                                                                            53                     44                  52                50                                                                                                     69                          59                                       50                                                                              42
  Sex                                                            F                                       F                                                                             F                                                                                        F                                                                                                                     M                                                                             F                      F                   F                 F                                                                                                      F                           F                                        F                                                                               M
  Race                                                           W                                       W                                                                             W                                                                                        B                                                                                                                     W                                                                             W                      W                   W                 W                                                                                                      W, H                        W, H                                     NR                                                                              W
  **MS history**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Duration of MS (years)                                         19                                      15                                                                            18                                                                                       8                                                                                                                     19                                                                            13                     9                   7                 16                                                                                                     8                           12                                       4                                                                               7
  Type                                                           RR                                      RR                                                                            RR                                                                                       RR                                                                                                                    RR                                                                            RR                     RR                  RR                PR                                                                                                     RR                          RR                                       RR                                                                              RR
  Disease-modifying therapy                                      Tecfidera, Avonex, Gilenya, Betaseron   Tecfidera, Tysabri, Betaseron, Copaxone, Avonex                               Tysabri                                                                                  Betaseron, Avonex, Copaxone                                                                                           No                                                                            Gilenya                Tysabri             Copaxone          Copaxone, Avonex, Novantrone                                                                           Avonex, Copaxone, Tysabri   Tysabri, Gilenya, Copaxone, Interferon   Copaxone, Tecfidera                                                             Betaseron, Copaxone, Rebif, Avonex, Gilenya
  **Diabetes history**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  Duration of diabetes (years)                                   2                                       12                                                                            5                                                                                        6                                                                                                                     Unknown                                                                       Unknown                Unknown             \~30              5                                                                                                      Unknown                     8                                        Unknown                                                                         28
  Type                                                           Type 2                                  Type 2                                                                        Type 2                                                                                   Type 2                                                                                                                Type 1                                                                        Type 2                 Type 2              Type 2            Type 2                                                                                                 Type 2                      Type 2                                   Type 2                                                                          Type 1
  Treatment                                                      No                                      Metformin                                                                     Metformin                                                                                Glucophage                                                                                                            Insulin pump, Novolog                                                         Metformin, glyburide   Meformin, Novolog   Humalog, Lantus   Levemir, insulin                                                                                       Byetta, Lantus, Humalog     Metformin                                Glipizide, Onglyza                                                              Insulin pump
  Does subject keep glucose monitoring log?                      No                                      Yes                                                                           No                                                                                       Yes                                                                                                                   No                                                                            No                     No                  Unknown           Unknown                                                                                                NR                          Unknown                                  Unknown                                                                         No
  **Prior steroid use**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Solu-Medrol                                                    Yes                                     Yes                                                                           Yes                                                                                      Yes                                                                                                                   Unknown                                                                       Yes                    Yes                 Unknown           Yes                                                                                                    Yes                         NR                                       Yes                                                                             Yes
  Prednisone                                                     NR                                      Yes                                                                           No                                                                                       Yes                                                                                                                   Unknown                                                                       Unknown                Unknown             Unknown           Yes                                                                                                    Yes                         Yes                                      No                                                                              No
  Complications from steroid use (any time in patient history)   NR                                      Elevations in blood glucose levels, modifications to diabetes meds required   Elevations in blood glucose levels, no modifications to meds, hypertension, osteopenia   Elevations in blood glucose levels, modifications to diabetes meds required, hypertension, mood disorder with mania   Elevations in blood glucose levels, modifications to diabetes meds required   NR                     GI upset, fatigue   Unknown           Elevations in blood glucose levels, unknown if modifications to diabetes meds, adrenal insufficiency   NR                          NR                                       Elevations in blood glucose levels, unknown if modifications to diabetes meds   Elevations in blood glucose levels, no modifications to diabetes meds

F, female; GI, gastrointestinal; H, Hispanic; M, male; NR, no response; PR, progressive relapsing; RR, relapsing remitting, W, white.

The duration of diabetes varied greatly, ranging from 2 to 30 years ([Table 1](#table1-2040622316644481){ref-type="table"}). Previous steroid treatment with either Solu-Medrol or prednisone was reported by 84.6% of patients (*n* = 11; 'unknown', *n* = 2); following administration of prior steroid treatment, seven reported elevated blood glucose levels and one reported gastrointestinal (GI) upset and fatigue.

Acthar Gel (80 units) was administered subcutaneously daily for a mean of 5.3 days (range 3--10 days) with 61.5% (*n* = 8) of patients reporting exacerbation resolution (all others 'unknown') at various times (range 7--90 days; [Table 2](#table2-2040622316644481){ref-type="table"}). A total of seven patients reported having no AEs following treatment with Acthar Gel. Four patients reported side effects and two of those experienced elevated blood glucose levels. Patient 8 (T1D) required an increase in insulin dose to correct blood glucose levels. A total of five patients' blood glucose levels were unknown, and no further assessments were conducted to evaluate the impact, if any, of the elevated glucose levels. Of the other reported AEs, only edema affected more than one individual (*n* = 2).

###### 

Acthar Gel treatment for multiple sclerosis relapse.

![](10.1177_2040622316644481-table2)

  Patient                                                          1            4                                                            5                                 7           8                        9          10         11        12        13         14                              15                                                 16
  ---------------------------------------------------------------- ------------ ------------------------------------------------------------ --------------------------------- ----------- ------------------------ ---------- ---------- --------- --------- ---------- ------------------------------- -------------------------------------------------- ----------
  Number of treatment days                                         10           5                                                            5                                 5           5                        3          3          3         5         10         5                               5                                                  5
  Time to resolution of exacerbation                               10 days      7--10 days                                                   Unknown                           14 days     7 days                   Unknown    Unknown    Unknown   47 days   Unknown    Resolved at 3-month follow up   30 days                                            30 days
  Side effects                                                     None noted   'Felt like I'd been hit by truck', mood swings, body aches   Swollen legs, 12 lb weight gain   None        Elevated blood glucose   None       None       NR        None      None       N/A                             Headache, Swelling, numbness, heaviness in chest   None
  Subject's assessment of relapse recovery                         Positive     Negative                                                     Equivocal                         Equivocal   Positive                 Positive   Positive   Unknown   Unknown   Positive   Positive                        Unknown                                            Positive
  Elevations in blood glucose level                                Unknown      No                                                           Yes                               No          Yes                      No         No         NR        Unknown   Unknown    Unknown                         Unknown                                            No
  Did diabetes meds need to be adjusted?                           No           No                                                           No                                No          Yes, increased           No         No         Unknown   Unknown   Unknown    Unknown                         Unknown                                            No
  Did subject record glucose levels during Acthar Gel treatment?   No           Yes                                                          Yes                               Yes         No                       No         Unknown    NR        Unknown   Unknown    Unknown                         Unknown                                            No

N/A, not applicable; NR, no response.

Approximately half of patients assessed their relapse recovery as 'positive' (53.8%, *n* = 7), two rated their recovery 'equivocal', one felt it was 'negative', and the remaining three patients' responses were unknown.

Limitations {#section9-2040622316644481}
-----------

The limitations of this study include that it was retrospective, which led to a low number of HCPs who responded to the survey. Additionally, this was an unvalidated pool of patients and much of the information that the survey was designed to acquire was not provided by the respondents. The questionnaire was brief and outstanding information could not be obtained prospectively; however, the obtained responses to this questionnaire suggest that blood glucose measurements should be routinely monitored during a relapse with concomitant T1D or T2D.

Discussion {#section10-2040622316644481}
==========

In this retrospective review of experiences, data were collected from HCPs who previously treated patients with relapsing MS with concomitant diabetes using Acthar Gel. The HCPs were asked to complete questionnaires based on previous patient-reported and HCP-recorded information that was collected during and after treatment. Although this resulted in some missing data, it allowed for a real-world, albeit limited, assessment of variables, such as how often patients' blood sugar levels are monitored during treatment in a clinical setting. Many patients in this study indicated that they did not keep a blood glucose log, and whether or not they monitored their glucose but did not record this information is not known. Without proper monitoring, especially during treatment for an MS exacerbation, blood glucose levels could shift significantly and lead to complications without proper medication adjustments. Both HCPs and patients with MS and diabetes should be made aware of the possible risks of treatment and the need for regular blood glucose monitoring during relapse therapy as well as when MS is stable.

The average age of patients at the time of MS onset is 30 years \[[@bibr23-2040622316644481]\], and 85% of individuals with the disease present with an RR MS course \[[@bibr5-2040622316644481]\]. Patients included in this study were slightly older than 30 years at the time of MS onset (mean 36 years) but predominately had RR MS, which is reflective of the general MS population. Most patients in this study were reported to have previously received corticosteroids for treatment of an MS relapse (corticosteroid treatment status was 'unknown' for two patients) that resulted in AEs, including elevations in blood glucose levels. Following treatment with Acthar Gel, only two patients were reported as having elevated blood glucose levels by the HCPs, while seven of these patients previously experienced hyperglycemia with corticosteroid treatment.

The majority of patients taking Acthar Gel experienced resolution of their acute MS exacerbation within a similar timeframe to that typically seen with corticosteroids. Because this patient population either experienced AEs or did not respond adequately to previous treatments with steroids, these data suggest that Acthar Gel may be a therapeutic option for MS relapse in patients with diabetes and who do not tolerate or adequately respond to standard corticosteroid treatments.

The AEs that occurred in this study that have previously been noted with Acthar Gel include swelling or weight gain and elevated blood glucose. Both patients who experienced elevated blood glucose following Acthar Gel treatment also had increases in blood glucose in response to their prior corticosteroid treatment. Additionally, the patient who required an increase in insulin dosage with Acthar Gel treatment (patient 8) was one of a number of patients who needed modifications to diabetes medications following prior corticosteroid therapy. Because five patients' blood glucose levels were not available during treatment, further studies are required to assess the effects of Acthar Gel on blood glucose levels in this population.

All patients in this study did not tolerate or respond to previous corticosteroid treatment and only one patient rated his or her experience with Acthar Gel as negative; therefore, future prospective studies on the use of Acthar Gel to relieve MS exacerbations in patients with diabetes would be valuable. Practical design of such studies should include close monitoring of blood glucose levels during treatment, changes made to diabetes medications, AEs, and patient-reported outcomes regarding experiences during treatment.

The majority of patients (*n* = 8) in this study experienced timely resolution of their MS exacerbations with few AEs. These results are of interest because this patient population encountered complications, AEs, or lack of efficacy during previous steroid treatment. Data from this study population underscore the need for prospective studies to determine the necessity of close blood glucose monitoring during relapse treatment, as this could help to determine the best approach to managing MS exacerbations in steroid-intolerant patients. Additional prospective data on the response to Acthar Gel treatment among patients who experience an MS relapse and have either T1D or T2D are necessary to provide more clinical insight.
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Questionnaire: Acthar Gel Use in Multiple Sclerosis Patients with Diabetes

Year of Birth \_\_\_\_\_\_\_\_\_

Gender

1.  □ Male

2.  □ Female

Race

1.  □ White

2.  □ Black

3.  □ Hispanic

4.  □ Non-Hispanic

5.  □ Other

**Multiple Sclerosis History**

-   Year of Diagnosis \_\_\_\_\_\_\_\_\_

-   Type of Multiple Sclerosis□ Relapsing-Remitting□ Primary Progressive□ Secondary Progressive□ Progressive-Relapsing

-   Disease Modifying Treatment□ Yes List: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No

**Diabetes History**

-   Year of Diagnosis \_\_\_\_\_\_\_\_\_

-   Type of Diabetes□ Type I□ Type II

-   Treatment for diabetes□ Yes List: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_□ No

-   Does subject keep a glucose monitoring log?□ Yes□ No

**Prior Steroid Use**

-   Solu-Medrol□ Yes□ No

-   Prednisone□ Yes□ No

-   Complications from steroid use (please check all that apply):□ Elevations in blood glucose levels

If yes, were modifications to diabetes medications required?

1.    □ Yes

2.    □ No

3.  □ Hypertension

4.  □ Osteopenia

5.  □ Osteoporosis

6.  □ Mood disorder

If yes, was there evidence of mania?

1.  □ Yes

2.  □ No

**Acthar Gel Treatment for Multiple Sclerosis Relapse**

-   Route of Administration□ Subcutaneous□ Intramuscular
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```
-   Number of treatment days

\_\_\_\_\_\_\_\_\_\_\_\_\_\_days

-   Time to resolution of exacerbation

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_days

-   Please list any side effects present in the space below

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

-   Subject's assessment of relapse recovery□ Positive□ Negative□ Equivocal

-   During Acthar Gel treatment, were there elevations in blood glucose level?□ Yes□ No

-   Did diabetes medications need to be adjusted?□ Yes □ Increased □ Decreased□ No

-   Did subject record blood glucose levels during Acthar Gel treatment?□ Yes□ No
